Gordiienko Inna, Shlapatska Larysa, Kholodniuk Valeriia, Sklyarenko Lilia, Gluzman Daniel F, Clark Edward A, Sidorenko Svetlana P
Department of Molecular and Cellular Pathobiology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Department of Oncohematology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.
PLoS One. 2017 Oct 5;12(10):e0185940. doi: 10.1371/journal.pone.0185940. eCollection 2017.
Cell surface expression of CD150 and CD180 receptors in chronic lymphocytic leukemia (CLL) associates with mutational IGHV status and favourable prognosis. Here we show a direct correlation between cell surface expression and colocalization of these receptors on CLL B cells. In the absence of CD150 and CD180 on the cell surface both receptors were expressed in the cytoplasm. The CD150 receptor was colocalized with markers of the endoplasmic reticulum, the Golgi apparatus and early endosomes. In contrast, CD180 was detected preferentially in early endosomes. Analysis of CD150 isoforms differential expression revealed that regardless of CD150 cell surface expression the mCD150 isoform with two ITSM signaling motifs was a predominant CD150 isoform in CLL B cells. The majority of CLL cases had significantly elevated expression level of the soluble sCD150, moreover CLL B cells secrete this isoform. CD150 or CD180 crosslinking on CLL B cells alone led to activation of Akt, mTORC1, ERK1/2, p38MAPK and JNK1/2 networks. Both CD150 and CD180 target the translation machinery through mTOR independent as well as mTOR dependent pathways. Moreover, both these receptors transmit pro-survival signals via Akt-mediated inhibition of GSK3β and FOXO1/FOXO3a. Unexpectedly, coligation CD150 and CD180 receptors on CLL B cells led to mutual inhibition of the Akt and MAPK pathways. While CD150 and CD180 coligation resulted in reduced phosphorylation of Akt, ERK1/2, c-Jun, RSK, p70S6K, S6RP, and 4E-BP; it led to complete blocking of mTOR and p38MAPK phosphorylation. At the same time coligation of CD150 and CD40 receptors did not result in Akt and MAPK inhibition. This suggests that combination of signals via CD150 and CD180 leads to blocking of pro-survival pathways that may be a restraining factor for neoplastic CLL B cells propagation in more than 50% of CLL cases where these receptors are coexpressed.
慢性淋巴细胞白血病(CLL)中CD150和CD180受体的细胞表面表达与IGHV突变状态及良好预后相关。在此我们展示了这些受体在CLL B细胞上的细胞表面表达与共定位之间的直接关联。在细胞表面不存在CD150和CD180时,两种受体均在细胞质中表达。CD150受体与内质网、高尔基体和早期内体的标志物共定位。相比之下,CD180优先在早期内体中被检测到。对CD150异构体差异表达的分析显示,无论CD150的细胞表面表达情况如何,具有两个ITSM信号基序的mCD150异构体是CLL B细胞中主要的CD150异构体。大多数CLL病例中可溶性sCD150的表达水平显著升高,此外CLL B细胞会分泌这种异构体。单独对CLL B细胞进行CD150或CD180交联会导致Akt、mTORC1、ERK1/2、p38MAPK和JNK1/2信号通路的激活。CD150和CD180均通过不依赖mTOR以及依赖mTOR的途径靶向翻译机制。此外,这两种受体均通过Akt介导的对GSK3β和FOXO1/FOXO3a的抑制来传递促生存信号。出乎意料的是,对CLL B细胞上的CD150和CD180受体进行共交联会导致Akt和MAPK信号通路的相互抑制。虽然CD150和CD180共交联导致Akt、ERK1/2、c-Jun、RSK、p70S6K、S6RP和4E-BP的磷酸化减少;但它导致mTOR和p38MAPK磷酸化完全被阻断。同时,CD150和CD40受体的共交联并未导致Akt和MAPK的抑制。这表明通过CD150和CD180的信号组合会导致促生存信号通路的阻断,这可能是在超过50%共表达这些受体的CLL病例中肿瘤性CLL B细胞增殖的一个限制因素。